Cancer Monoclonal Antibodies Market - Forecast(2021 - 2026)

Report Code: HCR 12157 Report Format: PDF + Excel (Delivery in 48 Hrs)

Cancer Monoclonal Antibodies Market Overview

Cancer Monoclonal Antibodies Market size is estimated to reach $69.3 Billion by 2025, growing at a CAGR of 10.2% during the forecast period 2020-2025. Monoclonal Antibody are made by cloning a unique white blood cell. These are molecules produced in laboratory; engineered to serve as substitute antibodies that can restore and also enhance the immune system’s attack on cancer cells. Technological advancements in genetic sequencing and target gene selection, growing preference towards the specificity of monoclonal antibodies to target cancer, rise in the government initiatives, increase in the female geriatric population, rise in the prevalence of breast cancer and rise in the adoption of unhealthy lifestyle are the factors that are set to drive the growth of the global market for the forecast period 2020-2025.

Cancer Monoclonal Antibodies Market Report Coverage

The report: “Cancer Monoclonal Antibodies Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Monoclonal Antibodies Market. 
By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Others.
By Therapy: Bevacizumab, Rituximab, Trastuzumab, Panitumumab, Cetuximab, Others.
By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others.
By Geography: North America, Asia-Pacific, Europe, and Rest of World (ROW).

Key Takeaways

  • Geographically, North America Cancer Monoclonal Antibodies Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to the high demand.
  • The growing preference towards the specificity of monoclonal antibodies to target cancer is likely to aid in the market growth of Cancer Monoclonal Antibodies Market.
  • High cost of products is the constraint likely to affect the growth of the market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Cancer Monoclonal Antibodies Market report.

Cancer Monoclonal Antibodies Market Segment Analysis - By Type

Based on the Type, the Murine Antibodies segment held the largest share in 2019 owing to the factors such as, prominent role in the development of modern antibody production techniques and enhancing the potential of use of immunoglobins for various applications. It also enhances the serum half-life of mAbs, which is driving the demand for these antibodies. Humanized Antibodies is set to be the fastest growing with a CAGR of 10.7% during the forecast period 2020-2025 owing to incorporation of advanced technologies such as phase or yeast display.

Cancer Monoclonal Antibodies Market Segment Analysis - By Application

Based on the Application, Breast Cancer segment held the largest share in 2019 owing to the factors such as growing exposure to harmful radiation, lack of physical exercise, rise in the adoption of unhealthy lifestyle, increase in the investment by the major companies, growing government initiatives and rise in the female geriatric population. It is also set to be growing with a fastest CAGR during the forecast period 2020-2025.

Cancer Monoclonal Antibodies Market Segment Analysis - By Geography

Based on the Geography, North America held the largest share in 2019 with share of 36.4%. The growth in this segment is owing to the factors such as technological advancements in genetic sequencing and target gene selection, rise in the investment by the major players and rise in the female geriatric population. Asia-Pacific is estimated to be the fastest growing segment owing to the factors such as rise in the government initiatives, rising prevalence of cancer and growing preference towards the specificity of monoclonal antibodies to target cancer.

Cancer Monoclonal Antibodies Market Drivers

Growing preference towards the specificity of monoclonal antibodies to target cancer

The growing preference towards the specificity of monoclonal antibodies to target cancer is estimated to enhance the growth of Cancer Monoclonal Antibodies Market. Advancements in technology and rise in the female geriatric population are also the factors which enhance the growth of Cancer Monoclonal Antibodies Market.

Increase in the investment in research and development activities of genomic studies

There is a rapid rise in the investment in research and development activities of genomic studies owing to the growing demand. This led to rapid increase in the growth of Cancer Monoclonal Antibodies Market. Rise in the prevalence of breast cancer is also estimated to enhance the growth of the Cancer Monoclonal Antibodies Market.

Cancer Monoclonal Antibodies Market Challenges

High costs

High costs involved in the development of these monoclonal antibodies for the treatment of cancer is one of the major factors that is estimated to reduce the growth of the Cancer Monoclonal Antibodies Market. The growing need of additional cell culture and purification procedures is also said to reduce the growth of the Cancer Monoclonal Antibodies Market.

Cancer Monoclonal Antibodies Industry outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Cancer Monoclonal Antibodies Market. Key companies of this market are ImmunoGen Inc, GlaxoSmithKline, Merck & Co Inc, Spectrum Pharmaceuticals, Novartis AG, Amgen Inc, Roche Holding, Seattle Genetics, Lifeline Scientific, Eli Lilly and Company, among others.

Acquisitions/Product Launches:

  • In 2016, ImmunoGen Inc has entered into an agreement with Merck for the assessment of mirvetuximab soravtansine for the treatment of patients with FRα-positive ovarian cancer.
  • In 2020, Merck has launched trastuzumab biosimilar, which is a monoclonal antibody used to treat certain breast cancers.
 
For more Lifesciences and Healthcare Market reports - Please click here
1. Cancer Monoclonal Antibodies Market - Overview
    1.1 Definitions and Scope
2. Cancer Monoclonal Antibodies Market - Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trends by Type
    2.3 Key trends by Application
    2.4 Key trends by Geography
3. Cancer Monoclonal Antibodies Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Cancer Monoclonal Antibodies Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Cancer Monoclonal Antibodies Market – Industry Market Entry Scenario Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Cancer Monoclonal Antibodies - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Cancer Monoclonal Antibodies Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Cancer Monoclonal Antibodies Market – By Type (Market Size – $Million/$Billion)
    8.1 Murine Antibodies
    8.2 Chimeric Antibodies
    8.3 Humanized Antibodies
    8.4 Others
9. Cancer Monoclonal Antibodies Market – By Therapy (Market Size – $Million/$Billion)
    9.1 Bevacizumab
    9.2 Rituximab
    9.3 Trastuzumab
    9.4 Panitumumab
    9.5 Cetuximab
    9.6 Others
10. Cancer Monoclonal Antibodies Market – By Application (Market Size – $Million/$Billion)
    10.1 Breast Cancer
    10.2 Blood Cancer
    10.3 Liver Cancer
    10.4 Brain Cancer
    10.5 Colorectal Cancer
    10.6 Others
11. Cancer Monoclonal Antibodies Market - By Geography (Market Size – $Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Cancer Monoclonal Antibodies Market - Entropy
13. Cancer Monoclonal Antibodies Market – Industry/Segment Competition Landscape  Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Cancer Monoclonal Antibodies Market – Key Company List by Country Premium
15. Cancer Monoclonal Antibodies Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global MARKET SEGMENTATION Market 2019-2024 ($M)
1.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Global Industry Research
1.1.1 Murine Antibodies Market 2019-2024 ($M)
1.1.2 Chimeric Antibodies Market 2019-2024 ($M)
1.1.3 Humanized Antibodies Market 2019-2024 ($M)
1.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Global Industry Research
1.2.1 Bevacizumab Market 2019-2024 ($M)
1.2.2 Rituximab Market 2019-2024 ($M)
1.2.3 Trastuzumab Market 2019-2024 ($M)
1.2.4 Cetuximab Market 2019-2024 ($M)
1.2.5 Panitumumab Market 2019-2024 ($M)
1.2.7 Breast Cancer Market 2019-2024 ($M)
1.2.8 Blood Cancer Market 2019-2024 ($M)
1.2.9 Liver Cancer Market 2019-2024 ($M)
1.2.10 Brain Cancer Market 2019-2024 ($M)
1.2.11 Colorectal Cancer Market 2019-2024 ($M)
2.Global COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
3.Global MARKET SEGMENTATION Market 2019-2024 (Volume/Units)
3.1 Types of Monoclonal Antibody Market 2019-2024 (Volume/Units) - Global Industry Research
3.1.1 Murine Antibodies Market 2019-2024 (Volume/Units)
3.1.2 Chimeric Antibodies Market 2019-2024 (Volume/Units)
3.1.3 Humanized Antibodies Market 2019-2024 (Volume/Units)
3.2 Monoclonal Antibody Therapies Market 2019-2024 (Volume/Units) - Global Industry Research
3.2.1 Bevacizumab Market 2019-2024 (Volume/Units)
3.2.2 Rituximab Market 2019-2024 (Volume/Units)
3.2.3 Trastuzumab Market 2019-2024 (Volume/Units)
3.2.4 Cetuximab Market 2019-2024 (Volume/Units)
3.2.5 Panitumumab Market 2019-2024 (Volume/Units)
3.2.7 Breast Cancer Market 2019-2024 (Volume/Units)
3.2.8 Blood Cancer Market 2019-2024 (Volume/Units)
3.2.9 Liver Cancer Market 2019-2024 (Volume/Units)
3.2.10 Brain Cancer Market 2019-2024 (Volume/Units)
3.2.11 Colorectal Cancer Market 2019-2024 (Volume/Units)
4.Global COMPETITIVE LANDSCAPE Market 2019-2024 (Volume/Units)
5.North America MARKET SEGMENTATION Market 2019-2024 ($M)
5.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
5.1.1 Murine Antibodies Market 2019-2024 ($M)
5.1.2 Chimeric Antibodies Market 2019-2024 ($M)
5.1.3 Humanized Antibodies Market 2019-2024 ($M)
5.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
5.2.1 Bevacizumab Market 2019-2024 ($M)
5.2.2 Rituximab Market 2019-2024 ($M)
5.2.3 Trastuzumab Market 2019-2024 ($M)
5.2.4 Cetuximab Market 2019-2024 ($M)
5.2.5 Panitumumab Market 2019-2024 ($M)
5.2.7 Breast Cancer Market 2019-2024 ($M)
5.2.8 Blood Cancer Market 2019-2024 ($M)
5.2.9 Liver Cancer Market 2019-2024 ($M)
5.2.10 Brain Cancer Market 2019-2024 ($M)
5.2.11 Colorectal Cancer Market 2019-2024 ($M)
6.North America COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
7.South America MARKET SEGMENTATION Market 2019-2024 ($M)
7.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
7.1.1 Murine Antibodies Market 2019-2024 ($M)
7.1.2 Chimeric Antibodies Market 2019-2024 ($M)
7.1.3 Humanized Antibodies Market 2019-2024 ($M)
7.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
7.2.1 Bevacizumab Market 2019-2024 ($M)
7.2.2 Rituximab Market 2019-2024 ($M)
7.2.3 Trastuzumab Market 2019-2024 ($M)
7.2.4 Cetuximab Market 2019-2024 ($M)
7.2.5 Panitumumab Market 2019-2024 ($M)
7.2.7 Breast Cancer Market 2019-2024 ($M)
7.2.8 Blood Cancer Market 2019-2024 ($M)
7.2.9 Liver Cancer Market 2019-2024 ($M)
7.2.10 Brain Cancer Market 2019-2024 ($M)
7.2.11 Colorectal Cancer Market 2019-2024 ($M)
8.South America COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
9.Europe MARKET SEGMENTATION Market 2019-2024 ($M)
9.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
9.1.1 Murine Antibodies Market 2019-2024 ($M)
9.1.2 Chimeric Antibodies Market 2019-2024 ($M)
9.1.3 Humanized Antibodies Market 2019-2024 ($M)
9.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
9.2.1 Bevacizumab Market 2019-2024 ($M)
9.2.2 Rituximab Market 2019-2024 ($M)
9.2.3 Trastuzumab Market 2019-2024 ($M)
9.2.4 Cetuximab Market 2019-2024 ($M)
9.2.5 Panitumumab Market 2019-2024 ($M)
9.2.7 Breast Cancer Market 2019-2024 ($M)
9.2.8 Blood Cancer Market 2019-2024 ($M)
9.2.9 Liver Cancer Market 2019-2024 ($M)
9.2.10 Brain Cancer Market 2019-2024 ($M)
9.2.11 Colorectal Cancer Market 2019-2024 ($M)
10.Europe COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
11.APAC MARKET SEGMENTATION Market 2019-2024 ($M)
11.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
11.1.1 Murine Antibodies Market 2019-2024 ($M)
11.1.2 Chimeric Antibodies Market 2019-2024 ($M)
11.1.3 Humanized Antibodies Market 2019-2024 ($M)
11.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
11.2.1 Bevacizumab Market 2019-2024 ($M)
11.2.2 Rituximab Market 2019-2024 ($M)
11.2.3 Trastuzumab Market 2019-2024 ($M)
11.2.4 Cetuximab Market 2019-2024 ($M)
11.2.5 Panitumumab Market 2019-2024 ($M)
11.2.7 Breast Cancer Market 2019-2024 ($M)
11.2.8 Blood Cancer Market 2019-2024 ($M)
11.2.9 Liver Cancer Market 2019-2024 ($M)
11.2.10 Brain Cancer Market 2019-2024 ($M)
11.2.11 Colorectal Cancer Market 2019-2024 ($M)
12.APAC COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
13.MENA MARKET SEGMENTATION Market 2019-2024 ($M)
13.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
13.1.1 Murine Antibodies Market 2019-2024 ($M)
13.1.2 Chimeric Antibodies Market 2019-2024 ($M)
13.1.3 Humanized Antibodies Market 2019-2024 ($M)
13.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
13.2.1 Bevacizumab Market 2019-2024 ($M)
13.2.2 Rituximab Market 2019-2024 ($M)
13.2.3 Trastuzumab Market 2019-2024 ($M)
13.2.4 Cetuximab Market 2019-2024 ($M)
13.2.5 Panitumumab Market 2019-2024 ($M)
13.2.7 Breast Cancer Market 2019-2024 ($M)
13.2.8 Blood Cancer Market 2019-2024 ($M)
13.2.9 Liver Cancer Market 2019-2024 ($M)
13.2.10 Brain Cancer Market 2019-2024 ($M)
13.2.11 Colorectal Cancer Market 2019-2024 ($M)
14.MENA COMPETITIVE LANDSCAPE Market 2019-2024 ($M)

LIST OF FIGURES

1.US Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
2.Canada Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
3.Mexico Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
4.Brazil Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
5.Argentina Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
6.Peru Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
7.Colombia Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
8.Chile Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
9.Rest of South America Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
10.UK Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
11.Germany Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
12.France Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
13.Italy Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
14.Spain Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
15.Rest of Europe Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
16.China Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
17.India Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
18.Japan Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
19.South Korea Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
20.South Africa Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
21.North America Cancer Monoclonal Antibodies By Application
22.South America Cancer Monoclonal Antibodies By Application
23.Europe Cancer Monoclonal Antibodies By Application
24.APAC Cancer Monoclonal Antibodies By Application
25.MENA Cancer Monoclonal Antibodies By Application